Sign In
Buy TLTFF
$0.166
+0.0001 (+0.0602%)
At Close: Jun 23, 2026
Theralase brings on two Clinical Research Associates to advance bladder cancer trial
09:54am, Thursday, 02'nd May 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it has expanded its clinical team by hiring two Clinical Research Associates, Bhavya Bajantri and Sonia Keshwani. The Toronto-based p
Theralase(R) Expands Clinical Team
07:00am, Thursday, 02'nd May 2024
TORONTO, ON / ACCESSWIRE / May 2, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and d
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
07:00am, Wednesday, 24'th Apr 2024
TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase® Technologies Inc. ("Theralase® " or the "Company") (TSXV:TLT)(OTCQB:TLTFF)(FRA:TTX), a clinical stage pharmaceutical company dedicated to the r
Theralase granted Canadian patent for cancer vaccine technology
08:49am, Friday, 05'th Apr 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced it has received a Canadian patent for its cancer vaccine. The newly issued patent follows the previous issuance of a US patent in October
Theralase(R) Granted Canadian Cancer Vaccine Patent
07:00am, Friday, 05'th Apr 2024
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
Theralase Technologies Inc. (TLTFF) Q4 2023 Earnings Call Transcript
01:15pm, Wednesday, 03'rd Apr 2024
Theralase Technologies Inc. (OTCQX:TLTFF) Q4 2023 Earnings Conference Call April 3, 2024 11:00 AM ET Company Participants Matthew Perraton - Chairman of the Board Kristina Hachey - Chief Financial Off
Theralase targets completion of Study II enrollment this year for bladder cancer treatment Rudivar
09:18am, Wednesday, 27'th Mar 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) is eyeing regulatory approval for its lead asset, the bladder cancer treatment Rudivar, by 2026, according to its CFO. The Canadian pharmaceutical c
Theralase(R) Release's 4Q2023 Interim Financial Statements
07:00am, Wednesday, 27'th Mar 2024
TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research an
Theralase to present data from Phase 2 bladder cancer study at Advisory Board meetings
09:10am, Tuesday, 26'th Mar 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it will be hosting Advisory Board meetings at two upcoming urologic community forums to present data from its Phase 2 bladder cancer
TORONTO, ON / ACCESSWIRE / March 26, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and
Theralase Technologies donates two lasers to aid landmark Parkinson's trial
08:54am, Monday, 12'th Feb 2024
Theralase Technologies Inc, a clinical-stage pharma company focused on photo-dynamic compounds, has donated two of its pioneering TLC-2400 Cool Laser Therapy (CLT) systems to the University of Win
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
07:00am, Monday, 12'th Feb 2024
TORONTO, ON / ACCESSWIRE / February 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research
Theralase Technologies brings on Dr. Michael Jewett to consult on Phase 2 bladder cancer study
08:39am, Thursday, 08'th Feb 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that Dr. Michael Jewett has joined the company as an independent consultant to assist it in completing patient enrollment for its Phase 2
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
07:00am, Thursday, 08'th Feb 2024
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
04:35pm, Monday, 05'th Feb 2024
TORONTO, ON / ACCESSWIRE / February 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research
